Safety and Efficacy of CJ Smallpox Vaccine in Previously Vaccinated Healthy Volunteers
Status:
Completed
Trial end date:
2011-12-01
Target enrollment:
Participant gender:
Summary
The currently available stock of smallpox vaccine would be insufficient in the face of an
incident of smallpox attack. Thus, new manufacturing methods for smallpox vaccine are
urgently needed because previous manufacturing methods using calf lymph are no longer
acceptable in the view of current standards. Recently, CJ corporation in Republic of Korea
has developed cell-culture derived smallpox vaccine (CJ-50300) which was manufactured by
infecting MRC-5 cells. The aim of this clinical trial were to assess safety, reactogenicity,
and immunogenicity of CJ-50300 in previously vaccinated healthy volunteers